Ramucirumab DP (IMC-1121B) — Competitive Intelligence Brief

Ramucirumab DP (IMC-1121B) (Ramucirumab DP (IMC-1121B)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: VEGF inhibitor. Area: Oncology.

phase 3 VEGF inhibitor VEGFR2 Oncology Biologic

Target snapshot

Ramucirumab DP (IMC-1121B) (Ramucirumab DP (IMC-1121B)) — Eli Lilly and Company. Ramucirumab DP is a monoclonal antibody that targets and binds to vascular endothelial growth factor receptor 2 (VEGFR2), inhibiting angiogenesis.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Ramucirumab DP (IMC-1121B) TARGET	Ramucirumab DP (IMC-1121B)	Eli Lilly and Company	phase 3	VEGF inhibitor	VEGFR2
REGORAFENIB	REGORAFENIB		marketed		RET, VEGFR1, VEGFR2, VEGFR3, KIT, PDGFR-alpha, PDGFR-beta, FGFR1, FGFR2, TIE2, DDR2, TrkA, Eph2A, RAF-1, BRAF, BRAF V600E, SAPK2, PTK5, Abl, CSF1R	2012-01-01
Sutent	Sunitinib Malate	Pfizer	marketed	Small molecule kinase inhibitor	Receptor tyrosine kinases (RTKs): PDGFRα, PDGFRβ, VEGFR1, VEGFR2, VEGFR3, KIT, FLT3, CSF-1R, RET	2006-01-01
Ramucirumab (IMC-1211B) DP	Ramucirumab (IMC-1211B) DP	Eli Lilly and Company	phase 3	VEGFR2 inhibitor (monoclonal antibody)	VEGFR2 (Vascular Endothelial Growth Factor Receptor 2)
Camrelizumab and Apatinib	Camrelizumab and Apatinib	Chinese Academy of Medical Sciences	phase 3	PD-1 inhibitor + VEGFR2 tyrosine kinase inhibitor combination	PD-1 (camrelizumab); VEGFR2 (apatinib)
Vandetanib (SAR390530)	Vandetanib (SAR390530)	Genzyme, a Sanofi Company	phase 3	Tyrosine kinase inhibitor	RET, VEGFR2, EGFR
apatinib;etoposide and cisplatin	apatinib;etoposide and cisplatin	Third Military Medical University	phase 3	Tyrosine kinase inhibitor (apatinib) combined with chemotherapy (etoposide and cisplatin)	VEGFR2 (apatinib); Topoisomerase II (etoposide); DNA (cisplatin)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (VEGF inhibitor class)

1. Hoffmann-La Roche · 2 drugs in this class
2. Genentech, Inc. · 1 drug in this class
3. Genzyme, a Sanofi Company · 1 drug in this class
4. Innostellar Biotherapeutics Co.,Ltd · 1 drug in this class
5. Jiangsu HengRui Medicine Co., Ltd. · 1 drug in this class
6. Pfizer · 1 drug in this class
7. Eli Lilly and Company · 1 drug in this class
8. Seoul National University Bundang Hospital · 1 drug in this class